News and Trends 19 Sep 2022 Tokyo scientists reveal possible new direction for getting rid of cancer cells Scientists from Tokyo University of Science have revealed how autophagy regulates the elimination of transformed cells that can initiate cancer. The elimination is necessary to maintain tissue integrity. The scientists have found that intact autograph vacuoles are indispensable in mediating competitive elimination of the cancer cells. They also noted perturbation of autophagy prevents cell […] September 19, 2022 - 4 minutesmins - By Liza Laws Share WhatsApp Twitter Linkedin Email
News and Trends 19 Sep 2022 Taiwan-based Anyong Biotechnology first to employ seafood stem-cell freezing Anyong Biotechnology is the first company in its region to use the most advanced freezing technology in Asia, it was announced today (September 19). The aquatic food processing company based in Taiwan has employed Cells Alive System (CAS) technology from Japan. Originally a medical-grade technology for freezing stem cells, Anyong says CAS is highly praised […] September 19, 2022 - 3 minutesmins - By Liza Laws Share WhatsApp Twitter Linkedin Email
News and Trends 19 Sep 2022 GENFIT to acquire Versantis to expand liver disease portfolio GENFIT has entered into an exclusivity agreement with a view to acquire all the share capital and voting rights of Versantis, a private Swiss-based clinical stage biotechnology company focused on addressing the growing unmet medical needs in liver diseases. GENFIT said the acquisition fits its strategic vision of becoming a global leader in ACLF (acute-on-chronic […] September 19, 2022 - 4 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email
News and Trends 19 Sep 2022 Biologics manufacturing facility launched by Evotec SE in Toulouse Construction of a biologics manufacturing facility commenced on Friday (September 16). It is being built by Evotec at its Campus Curie in Toulouse, is the second facility of its kind, and the first in Europe. It will use Just – Evotec Biologics’ flexible J.POD technology to deliver clinical and commercial manufacturing capacity for biologics. Therapeutic […] September 19, 2022 - 2 minutesmins - By Liza Laws Share WhatsApp Twitter Linkedin Email
News and Trends 19 Sep 2022 Cyxone receives approval for phase 2b rheumatoid arthritis study Swedish biotech company Cyxone has received approval from the Medical Product Agency (Office for Registration of Medicinal Products, Medical devices and Biocides) and the Central Ethics Committee in Poland to start a clinical phase 2b study with its drug candidate Rabeximod, which is being developed as a treatment for rheumatoid arthritis (RA). “The approval is […] September 19, 2022 - 2 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email
News and Trends 19 Sep 2022 FDA approves Heron Therapeutics’ post-op nausea and vomiting drug Heron Therapeutics, Inc. says the U.S. Food and Drug Administration (FDA) has approved APONVIE (aprepitant) injectable emulsion, for intravenous use for the prevention of postoperative nausea and vomiting (PONV) in adults. Heron Therapeutics’ APONVIE is the first and only IV formulation of aprepitant for PONV prevention. Administered via a single 30-second IV injection, APONVIE reaches […] September 19, 2022 - 3 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email
News and Trends 19 Sep 2022 CellResearch Corporation announces positive results of phase I diabetic foot ulcer study CellResearch Corporation, a Singapore-based biopharma company says it has successfully closed the first phase I study for CorLiCyte, a stem cell therapy derived from umbilical cord lining stem cells, with research partners at the University of Colorado, Anschutz Medical Campus and ClinImmune Cell and Gene Therapy. CorLiCyte is in development for the treatment of serious […] September 19, 2022 - 3 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email
News and Trends 19 Sep 2022 FDA boosts Antengene pancreatic cancer treatment Biopharma company Antengene Corporation Limited says ATG-101, the company’s in-house developed novel PD-L1/4-1BB bispecific antibody, has been granted an orphan drug designation (ODD) by the U.S. Food and Drug Administration (FDA) for the treatment of pancreatic cancer. The company said the ODD will help Antengene facilitate regulatory communication with the FDA, accelerate the clinical development […] September 19, 2022 - 3 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email
News and Trends 19 Sep 2022 Bugworks Research and Cytecare Cancer Hospitals to set up cancer research center Bugworks Research Inc., a clinical stage biopharmaceutical company, and Cytecare Cancer Hospitals are set to collaborate by setting up a dedicated research center. Suresh Ramu, co-founder & CEO, Cytecare Cancer Hospitals, said: “We are excited to partner with Bugworks Research, in this inspiring endeavor to discover novel treatments for different types of cancers. In 2016, […] September 19, 2022 - 2 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email
News and Trends 16 Sep 2022 Marengo advancing its lead TCR activator into clinic after FDA clearance Marengo Therapeutics is advancing its lead TCR activator, STAR0602, into clinic following clearance of its investigational new drug (IND) application by the U.S. Food and Drug Administration (FDA). STAR0602 is a bi-functional fusion antibody that deploys a mechanism of T cell activation that has demonstrated potent single agent activity in PD-1 refractory settings in preclinical […] September 16, 2022 - 2 minutesmins - By Liza Laws Share WhatsApp Twitter Linkedin Email
News and Trends 16 Sep 2022 Regeneron and Sanofi announce published trial results in children with dermatitis Positive results from a phase 3 trial in children aged 6 months to five years old with uncontrolled moderate-to-severe dermatitis have been published. Regeneron Pharmaceuticals, Inc. and Sanofi made the announcement today (September 16) that the Lancet published details on the success of Dupixent (dupilumab). These data were the basis for the U.S. Food and […] September 16, 2022 - 3 minutesmins - By Liza Laws Share WhatsApp Twitter Linkedin Email
News and Trends 16 Sep 2022 Ghana first to benefit from Roche partnership with Jhpiego to improve cervical and breast cancer outcomes for women Roche has signed a memorandum of understanding (MoU) with the Johns Hopkins Program for International Education in Gynecology and Obstetrics (Jhpiego) to improve cervical and breast cancer outcomes in resource-constrained countries. Breast cancer is the most diagnosed cancer and the cause of the most cancer-related deaths in women. Similarly, cervical cancer is the fourth most […] September 16, 2022 - 3 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email